89bio reports Q3 EPS ($1.39), consensus (64c)

“We continue to execute on our three pivotal Phase 3 trials for pegozafermin in MASH and SHTG,” stated Rohan Palekar, CEO of 89bio (ETNB). “Building on the positive momentum from ENLIGHTEN and ENTRUST, we have made strategic additions to our Board of Directors and Executive Leadership Team, as well as bolstered our financial position with support from K2 HealthVentures. These efforts collectively underscore our confidence in pegozafermin’s anti-fibrotic and broad metabolic effects across multiple indications where significant opportunities remain to offer better treatment for those living with MASH and SHTG.”